Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VimRx Genomics Inc.

Division of Baxter International Inc.

Latest From VimRx Genomics Inc.

Termination Fees in Biotech Deals

We review recent payments made to prematurely end biotech licensing deals.

Columbia University

With Columbia's major revenue-producing patent set to expire, its tech transfer organization is focusing on Columbia-based start-ups to provide the next blockbuster.

VimRx: FIPCO or Financier?

VimRx's acquisition of Baxter's immunotherapy business is being touted by company officials as part of its transformation from a research-stage biotech to a fully integrated commercial enterprise. But others aren't so sure, saying the deal was driven more by Baxter's need to get the high R&D costs associated with its immunotherapy business off its books.
BioPharmaceutical Business Strategies

Pharma U.

Savvy venture capitalists, biotech firms, and pharmaceutical companies have long recognized universities as technology troves of untapped value. In the last year or so, universities have developed a heightened perception of their own value--and are increasingly willing to exploit it through creative dealmaking. A look at the previous six months of licenses and research agreements signed between universities and pharmaceutical companies.
BioPharmaceutical Medical Device
See All

Company Information